Payment overview · 2025
General Payments
$349.71
18 reported records · 8 companies
Healthcare provider profile · identity verified
Daniela V Weatherly, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOBILE, AL · NPI 1184691859
Verified facts
What the public records show
CMS Open Payments records show Daniela V Weatherly, MD received $349.71 in general payments during 2025 across 18 reported records.
Sumitomo Pharma America, Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $146.73 | 42.0% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.44 | 15.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.03 | 12.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.49 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.75 | 6.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.06 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.16 | 4.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.05 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.71 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $146.73 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 352 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 101 |
| Gabapentin | Gabapentin | 279 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 58 |
| Clonazepam | Clonazepam | 182 | 27 |
| Metformin Hcl | Metformin Hcl | 171 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 51 |
| Lisinopril | Lisinopril | 167 | 51 |
| Omeprazole | Omeprazole | 155 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 54 |
| Meloxicam | Meloxicam | 139 | 51 |
| Tramadol Hcl | Tramadol Hcl | 129 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 29 |
| Furosemide | Furosemide | 116 | 41 |
| Mounjaro | Tirzepatide | 110 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 20 |
| Potassium Chloride | Potassium Chloride | 104 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 13 |
| Losartan Potassium | Losartan Potassium | 99 | 34 |
| Trazodone Hcl | Trazodone Hcl | 96 | 32 |
| Carvedilol | Carvedilol | 92 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 91 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 33 |
| Methylprednisolone | Methylprednisolone | 89 | 69 |
| Levofloxacin | Levofloxacin | 88 | 62 |
| Azithromycin | Azithromycin | 83 | 65 |
| Ozempic | Semaglutide | 83 | 19 |
| Fluconazole | Fluconazole | 75 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 23 |
| Prednisone | Prednisone | 71 | 42 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 71 | 55 |
| Buspirone Hcl | Buspirone Hcl | 69 | 17 |
| Cefdinir | Cefdinir | 69 | 54 |
| Alprazolam | Alprazolam | 63 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 18 |
| Ondansetron Odt | Ondansetron | 60 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 23 |
| Allopurinol | Allopurinol | 49 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 16 |
| Famotidine | Famotidine | 48 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Diazepam | Diazepam | 43 | 12 |
| Clonidine Hcl | Clonidine Hcl | 41 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Simvastatin | Simvastatin | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Mupirocin | Mupirocin | 38 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Nystatin | Nystatin | 36 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Temazepam | Temazepam | 29 | suppressed |
| Topiramate | Topiramate | 29 | 12 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.71 · 18 records | Sumitomo Pharma America, Inc. | AREXVY, Auvelity, Cologuard Collection Kit, GEMTESA, LOREEV XR, QULIPTA, SHINGRIX, UBRELVY, Wegovy, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error